Tag: AbbVie

AbbVie is a pharmaceutical company that discovers, develops and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate into two publicly traded companies. The “new” Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based pharmaceutical manufacturer.

BioArctic Started Clinical Study for Parkinon’s Treatment

BioArctic AB announced that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805. The Phase 1 study in healthy volunteers wil...

Fifth BTD for AbbVie and Genentech Drug

AbbVie, a research-based global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted a fifth Breakthrough Therapy Designation (BTD) to venetoclax, for use in c...

CHMP’s Positive Opinion for AbbVie Med

CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission....

Big Pharma Answered for High Prices

U.S. senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate...

AbbVie and Voyager to Develop Treatment of Parkinson’s

AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, annou...

Priority Review for AbbVie’s NDA

abbvie office
AbbVie, a research-based global biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for upadacitin...

Pharma Alliance for Treatment of Multiple Myeloma

AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for th...

Big Pharma to Testify in High Drug Pricing Case

While congressional scrutiny on drug pricing is nothing new, the prospect of some of the pharmaceutical industry's highest-profile CEOs testifying on the issue will make for a must-watch event. In ...

Approved use of IMBRUVICA with Obinutuzumab for CLL/SLL

AbbVie, a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of IMBRUVICA® (ibrutinib) in combination with obinutuzumab ...

AbbVie and J&J’s Pancreatic Cancer Drug Failed Trial

AbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has hit a snag. In the phase III RESOLVE trial, Imbruvica (ibrutinib) was no...

AbbVie and Tizona to Develop Antibody for Cancer Treatment

AbbVie, a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc., a privately held immunotherapy company, announced on Jan. 3, 2019 that they have entered into a global, strate...

AbbVie presses charges against UK National Health Service

abbvie office
Abbvie, a global pharmaceutical company, is claiming that National Health Service (UK) breached procurement rules during a process seeking suppliers for hepatitis C treatment.

AbbVie and Morphic Therapeutic to cooperate on antifibrotic medications

AbbVie and Morphic Therapeutic (Massachusetts, USA) announced that the companies have entered into a research and development collaboration designed to advance a number of oral integrin therapeutics.

AbbVie obtains an exclusive license for novel antibody from Dutch biotech

argenx, a clinical-stage biotechnology company, announced the exercise by AbbVie of its exclusive license option to develop and commercialize ARGX-115.

Tolero Pharmaceuticals enters into clinical research collaboration with AbbVie

Tolero Pharmaceuticals has entered into a clinical research collaboration with AbbVie exploring the potential of combination therapy with AbbVie's venetoclax and Tolero's alvocidib.

AbbVie and R-Pharm will launch the full-cycle manufacturing of Kaletra in Russia

AbbVie, a global research biopharmaceutical company, and R-Pharm Group announced the completion of technology transfer for manufacturing Kaletra intended for treatment of HIV/AIDS infection in adult patients.